Convalescent plasma for adults with acute COVID-19 respiratory illness (CONCOR-1): study protocol for an international, multicentre, randomized, open-label trial
DiscussionThis trial will determine whether CCP will reduce intubation or death non-intubated adults with COVID-19. The trial will also provide information on the role of and thresholds for SARS-CoV-2 antibody titres and neutralization assays for donor qualification.Trial registrationClinicaltrials.govNCT04348656. Registered on 16 April 2020.
Source: Trials - Category: Research Source Type: clinical trials
More News: Coronavirus | COVID-19 | Ebola | Flu Pandemic | Hospitals | Influenza | Intensive Care | MERS | Middle East Health | Pandemics | Pneumonia | Research | Respiratory Medicine | SARS | Study